Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study

PURPOSE: There remains a lack of consensus among experts regarding the optimal therapeutic approach for Mantle cell lymphoma (MCL) after failure of covalent Bruton Tyrosine Kinase inhibitor (cBTKi)-based therapy. This study was designed to examine patient characteristics, current treatment patterns,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hess, Lisa M., Chen, Yongmei, Abada, Paolo B., Konig, Heiko, Walgren, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812614/
https://www.ncbi.nlm.nih.gov/pubmed/36620778
http://dx.doi.org/10.1155/2022/8262787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812614/
https://www.ncbi.nlm.nih.gov/pubmed/36620778
http://dx.doi.org/10.1155/2022/8262787

Ejemplares similares